KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Net Margin (2016 - 2025)

Historic Net Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1461.25%.

  • Arbutus Biopharma's Net Margin rose 116400.0% to 1461.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 289.31%, marking a year-over-year increase of 8480900.0%. This contributed to the annual value of 1133.04% for FY2024, which is 7314700.0% down from last year.
  • Per Arbutus Biopharma's latest filing, its Net Margin stood at 1461.25% for Q3 2025, which was up 116400.0% from 23.3% recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Net Margin high stood at 23.3% for Q2 2025, and its period low was 1472.89% during Q3 2024.
  • In the last 5 years, Arbutus Biopharma's Net Margin had a median value of 725.9% in 2021 and averaged 712.2%.
  • As far as peak fluctuations go, Arbutus Biopharma's Net Margin tumbled by -10412900bps in 2024, and later skyrocketed by 11697600bps in 2025.
  • Over the past 5 years, Arbutus Biopharma's Net Margin (Quarter) stood at 682.94% in 2021, then soared by 49bps to 351.19% in 2022, then crashed by -156bps to 900.33% in 2023, then grew by 12bps to 794.09% in 2024, then plummeted by -84bps to 1461.25% in 2025.
  • Its Net Margin stands at 1461.25% for Q3 2025, versus 23.3% for Q2 2025 and 1390.59% for Q1 2025.